HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study
RL Hamers, CL Wallis, C Kityo, M Siwale… - The Lancet infectious …, 2011 - thelancet.com
Background There are few data on the epidemiology of primary HIV-1 drug resistance after
the roll-out of antiretroviral treatment (ART) in sub-Saharan Africa. We aimed to assess the …
the roll-out of antiretroviral treatment (ART) in sub-Saharan Africa. We aimed to assess the …
[HTML][HTML] High rate of asymptomatic carriage associated with variant strain omicron
…, I Seocharan, LH Fisher, L Bunts, N Espy, CL Wallis… - MedRxiv, 2022 - ncbi.nlm.nih.gov
The early widespread dissemination of Omicron indicates the urgent need to better
understand the transmission dynamics of this variant, including asymptomatic spread among …
understand the transmission dynamics of this variant, including asymptomatic spread among …
Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a …
…, R Schuurman, KCE Sigaloff, CL Wallis… - The Lancet infectious …, 2012 - thelancet.com
Background The effect of pretreatment HIV-1 drug resistance on the response to first-line
combination antiretroviral therapy (ART) in sub-Saharan Africa has not been assessed. We …
combination antiretroviral therapy (ART) in sub-Saharan Africa has not been assessed. We …
Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa
KCE Sigaloff, RL Hamers, CL Wallis… - JAIDS Journal of …, 2011 - journals.lww.com
Objectives: This study aimed to investigate the consequences of using clinicoimmunological
criteria to detect antiretroviral treatment (ART) failure and guide regimen switches in HIV-…
criteria to detect antiretroviral treatment (ART) failure and guide regimen switches in HIV-…
Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies
…, KCE Sigaloff, AM Wensing, CL Wallis… - Clinical infectious …, 2012 - academic.oup.com
Background. Human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the
benefits of antiretroviral therapy (ART). This cohort study examined patterns of drug-resistance …
benefits of antiretroviral therapy (ART). This cohort study examined patterns of drug-resistance …
High asymptomatic carriage with the Omicron variant in South Africa
…, LH Fisher, L Bunts, N Espy, CL Wallis… - Clinical Infectious …, 2022 - academic.oup.com
We report a 23% asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS
CoV-2) Omicron carriage rate in participants being enrolled into a clinical trial in South Africa, 15…
CoV-2) Omicron carriage rate in participants being enrolled into a clinical trial in South Africa, 15…
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa
MA Price, CL Wallis, S Lakhi, E Karita… - AIDS research and …, 2011 - liebertpub.com
To characterize WHO-defined transmitted HIV drug resistance mutation (TDRM) data from
recently HIV-infected African volunteers, we sequenced HIV (pol) and evaluated for TDRM the …
recently HIV-infected African volunteers, we sequenced HIV (pol) and evaluated for TDRM the …
Key factors influencing the emergence of human immunodeficiency virus drug resistance in low-and middle-income countries
CL Wallis, C Godfrey, JE Fitzgibbon… - The Journal of …, 2017 - academic.oup.com
The emergence and spread of human immunodeficiency virus (HIV) drug resistance from
antiretroviral roll-out programs remain a threat to long-term control of the HIV-AIDS epidemic in …
antiretroviral roll-out programs remain a threat to long-term control of the HIV-AIDS epidemic in …
ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)–infected participants with HIV-1 RNA< …
…, A Nyaku, B Bezins, CL Wallis… - Clinical Infectious …, 2018 - academic.oup.com
Background Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment
with dolutegravir plus lamivudine. Methods A5353 is a phase 2, single-arm, pilot study …
with dolutegravir plus lamivudine. Methods A5353 is a phase 2, single-arm, pilot study …
[HTML][HTML] HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing
…, N Ndembi, RL Hamers, TF Rinke de Wit, CL Wallis… - PloS one, 2015 - journals.plos.org
The increasing prevalence of acquired and transmitted HIV-1 drug resistance is an obstacle
to successful antiretroviral therapy (ART) in the low- and middle-income countries (LMICs) …
to successful antiretroviral therapy (ART) in the low- and middle-income countries (LMICs) …